Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  BG Medicine       

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

BG Medicine Announces One-for-Four Reverse Stock Split

share with twitter share with LinkedIn share with facebook
share via e-mail
07/08/2015 | 11:01pm CEST

WALTHAM, Mass., July 8, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced the effectiveness of a one-for-four reverse stock split of its common stock. The reverse stock split took effect at 5:00 pm Eastern Time on July 8, 2015 and the Company's common stock will open for trading on the NASDAQ Capital Market on July 9, 2015 on a post-split basis.

The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market. As a result of the reverse stock split, every four shares of the Company's common stock issued and outstanding prior to the opening of trading on July 9, 2015 will be consolidated into one issued and outstanding share, except to the extent that the reverse stock split results in any of the Company's stockholders owning a fractional share, which would be rounded up to the next highest whole share. In connection with the reverse stock split, there will be no change in the nominal par value per share of $0.001.

Trading of the Company's common stock on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Thursday, July 9, 2015, under the existing trading symbol "BGMD" but with a new CUSIP number 08861T206. The reverse stock split reduces the number of shares of the Company's common stock outstanding from approximately 34.6 million pre-reverse split shares to approximately 8.6 million post-reverse split shares.

The Company has retained its transfer agent, Computershare Trust Company, N.A. ("Computershare"), to act as its exchange agent for the reverse split. Computershare will provide stockholders of record as of the effective date a letter of transmittal providing instructions for the exchange of their certificates. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split.

The reverse stock split was approved within a range of one-for-two to one-for-six by the Company's stockholders at the 2015 Annual Meeting of Stockholders held on July 7, 2015 and the specific ratio of one-for-four was subsequently approved by the Company's Board of Directors. For more information regarding the reverse stock split, please refer to the Company's definitive proxy statement filed with the Securities and Exchange Commission on Schedule 14A on June 9, 2015.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.BG-Medicine.com.

The BG Medicine Inc. logo is available for download here.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the reverse stock split of the Company's common stock and its intended purpose. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include, among other things, the factors discussed under the heading "Risk Factors" contained in BG Medicine's annual report and quarterly reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and BG Medicine disclaims any obligation to update the information contained in this press release as new information becomes available.

CONTACT: Stephen Hall, EVP & Chief Financial Officer
         (781) 890-1199

BG Medicine, Inc. logo

© GlobeNewswire 2015
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BG MEDICINE
2015BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional I..
2015BG MEDICINE : Announces Business Update Conference Call Information
2015BG MEDICINE : License and Distribution Agreement Amended
2015BG MEDICINE : Reports Third Quarter 2015 Financial Results
2015License and Distribution Agreement Amended
2015BG Medicine Reports Third Quarter 2015 Financial Results
2015BG Medicine Announces Business Update Conference Call Information
2015BG MEDICINE, INC. : BG Medicine Due Diligence Report: Quietly Making Headway - ..
2015BG Medicine to Begin Trading on the OTCQB
2015BG Medicine Provides Business Update and Reports Second Quarter 2015 Financia..
More news
News from SeekingAlpha
2015Midday Gainers / Losers 
2015BG MEDICINE REVERSE SPLITS STOCK 1 : 4 effective today 
2015BG Med's largest customer bankrupt but galectin-3 purchases continue (for now.. 
2015BG MEDICINE : A Takeover Target? 
2015BG Medicine's (BGMD) CEO Paul Sohmer on Q1 2015 Results - Earnings Call Trans.. 
Duration : Period :
BG Medicine Technical Analysis Chart | 4-Traders
Income Statement Evolution
Paul R. Sohmer President, Chief Executive Officer & Director
Harry W. Wilcox Chairman
Stephen P. Hall Chief Financial Officer, Treasurer & EVP
Aram S. Adourian Chief Scientific Officer & Senior Vice President
Stelios B. Papadopoulos Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055